

Sustainable Medical Ultrasound Coupling Spray for Infection Control & Green Healthcare seeks strategic partners, distributors, & healthcare collaborators in Japan to support market access, regulatory registration, & potential joint research or clinical pilots

Summary

Profile type

Business Offer

Company's country

Ireland

POD reference

BOIE20251006025

Profile status

PUBLISHED

Type of partnership

Commercial agreement

Targeted countries

• Japan

Contact Person

Noriko MITA

Term of validity

6 Oct 2025**6 Oct 2026**

Last update

6 Oct 2025

General Information

Short summary

This Irish Company has developed PoCUS ECCO Spray, a patented, CE-approved ultrasound coupling agent that replaces traditional gel. The spray delivers equivalent imaging quality while eliminating contamination risk, residue, and waste. It is validated by leading handheld ultrasound manufacturers and aligns with new NHS infection-control and sustainability standards.

The company seeks strategic partners, distributors, and healthcare collaborators in Japan.

Full description

PoCUS ECCO Spray is a water-based, skin-friendly ultrasound coupling medium delivered as a fine mist/spray from a 50 ml pump action bottle. Unlike gels, it leaves no residue and evaporates naturally within minutes, enabling faster, cleaner, and safer examinations. It has been independently validated by Clarius Mobile Health (Canada) and approved as a Class I CE medical device for external ultrasound use.

The company is seeking:

- Japanese distributors specialised in ultrasound consumables or infection-control products;
- Hospital or academic collaborators for pilot evaluations;
- Corporate partners in diagnostic imaging or infection-prevention technology interested in joint development or licensing.

Comments Regarding IPR Status

Inventor Prof. Helmut Haas assigned full global rights to the company.

Patent portfolio protects formulation and delivery mechanism through 2040.

Partner Sought – Type and Role

- Distributor / Commercial Partner: manage sales, registration, and customer training in Japan.
- Hospital / University Partner: conduct comparative imaging or infection-control evaluations.
- Industrial Partner: explore co-development for specialised spray formulations or private-label use.

Advantages and innovations

The advantages of this technology are:

- Infection control: no nozzle-to-skin contact; eliminates contamination risk from gels.
- Workflow efficiency: "Spray and Scan" in seconds; no clean-up or paper waste.
- Sustainability: uses ~7x less liquid per exam and reduces clinical waste by 90%.
- Device-agnostic compatibility: proven with Clarius and Butterfly IQ handhelds.

Along with testing by Health Innovation Hub Ireland on GE, Mindray, Philips, and Sonosite probes.

- Patient comfort: no cold, sticky residue; improves perception of ultrasound at bedside.
- Validated & patented: global IP to 2040; tested and CE-certified for clinical use.

Stage of Development:

- Commercially available and CE-marked in the EU / UK.
- Patents granted in the EU, UK, Japan (2025 Patent No. 7695353), Turkey, and pending in USA and China.
- Initial distributor network established in Europe, Middle East, Africa, and Australia.
- Ready for market entry and clinical evaluation in Japan 2025–26.

Comments Regarding Stage of Development:

- Field pilots underway with NHS England and Health Innovation Hub Ireland.
- Manufacturing, QA and fulfilment infrastructure already in place for international scaling.

Technical specification or expertise sought

Stage of development

Already on the market

Sustainable Development goals

- **Goal 3: Good Health and Well-being**
- **Goal 9: Industry, Innovation and Infrastructure**

IPR Status

IPR granted

IPR Notes

IPR Status:

- **Granted patents:** EU, UK, Japan (No. 7695353), Turkey; pending USA & China.
- **Trademarks registered for PoCUS ECCO Spray.**

Comments Regarding IPR Status:

- **Inventor Prof. Helmut Haas assigned full global rights to the company.**
- **Patent portfolio protects formulation and delivery mechanism through 2040.**

Partner Sought

Expected role of the partner

- **Distributor / Commercial Partner:** manage sales, registration, and customer training in Japan.
- **Hospital / University Partner:** conduct comparative imaging or infection-control evaluations.
- **Industrial Partner:** explore co-development for specialised spray formulations or private-label use.

Type of partnership

Commercial agreement

Type and size of the partner

- **Big company**
- **SME 11-49**
- **SME 50 - 249**
- **Other**

Dissemination

Technology keywords

- **06001005 - Diagnostics, Diagnosis**

Targeted countries

- **Japan**

Market keywords

- **05004003 - Laboratory equipment**
- **05004006 - Surgical instrumentation and equipment**
- **05004005 - Diagnostic equipment**
- **05002003 - Ultrasound imaging**

Sector groups involved

Media

Images



[Picture1.jpg](#)



[Picture2.png](#)